Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients.

Abstract

Two analogs of somatostatin (Ala2,D-Trp8,D-Cys14-Somatostatin and L-5F-Trp8-Somatostatin) infused into acromegalics at the rate of 4.5 micrograms/min suppressed arginine-stimulated growth hormone release more strongly than 6 micrograms/min somatostatin (110 +/- 11% and 129 +/- 14%, respectively). Under the same conditions the two somatostatin analogs induced a much smaller inhibition of insulin (33 +/- 13% and 44 +/- 18%) and glucagon (28 +/- 10% and 45 +/- 17%, respectively) release than somatostatin did. Somatostatin analogs with dissociated actions could be promising for the treatment of diseases such as acromegaly, diabetes mellitus and some ectopic hormone syndromes.

• Authors: B L Wajchenberg, F P Cesar, C E Leme, V C Borghi, V C Souza, I T Souza, D G Neto, O A Germek, D H Coy, A M Comaru-Schally
• Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (Horm Metab Res) Vol. 15 Issue 10 Pg. 471-4 (Oct 1983) ISSN: 0018-5043 [Print] Germany
• PMID: 6139329 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Insulin
• Somatostatin
• somatostatin, 5-fluoro-Trp(8)-
• somatostatin, Ala(2)-Trp(8)-Cys(14)-
• Growth Hormone
• Glucagon
• Arginine

Topics

• Acromegaly (blood, drug therapy)
• Adult
• Arginine
• Blood Glucose (metabolism)
• Female
• Glucagon (blood)
• Growth Hormone (blood)
• Humans
• Insulin (blood)
• Kinetics
• Male
• Somatostatin (analogs & derivatives, therapeutic use)